How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.


FimH - Expression of recombinant proteins on the surface of bacteria

Organization name

PROvendis GmbH



The expression and production of recombinant proteins in bacteria, such as E. coli is a long standing and well known procedure. However, expression in bacterial systems is limited due to cytoplasmic accumulation of the protein of interest (POI). Even though, various attempts have been made to prevent the accumulation of the desired protein in inclusion bodies, there is still no satisfactory solution available to overcome this problem.

The present invention enables the expression of POI on the cell surface of bacteria, thereby preventing the cytoplasmic and periplasmic accumulation. This is achieved by using an expression vector comprising the bacterial cell-surface protein FimH and the POI. Bacterial expression of this fusion protein leads to the localization of the protein on the cell surface. Thus, thed from the surface of the bacterial cells or, alternatively, be isolated from the bacterial cell medium subsequent to secretion.

Thus, this novel strategy allows the production of recombinant proteins having a natural folding structure and the same biological activity as a natural protein.

Commercial Opportunities

This invention offers a novel approach for the production of recombinant proteins,which can be used for the production of reagents suitable for diagnostics and therapy.

Current Status

On behalf of the University Hospital Cologne, PROvendis offers access for commercial use in terms of a license as well as research collaboration to innovative companies. In case of interest we will be pleased to inform you about the patent status.

Competitive Advantages

  • Recombinant protein with
    • o Natural folding structure
    • o Natural biological activity
  • Recombinant protein expression on the bacterial cell surface
  • No cytoplasmic or periplasmic protein accumulation

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.


latest entries